Events & Presentations

Events & Presentations

Upcoming Events

More events are coming soon.

Corporate Presentation

Date Documents
Aug 06, 2020
Dynavax Technologies Corporate Presentation

Archived Events

Date Event Details
Aug 6, 2020
at 4:30 PM EDT
Dynavax Technologies Second Quarter 2020 Financial Results
Listen to webcast
Jun 25, 2020
at 10:50 AM EDT
H.C. Wainwright Fireside Chat Series
Listen to webcast
Jun 9, 2020
at 12:00 PM CDT
William Blair 40th Annual Growth Stock Conference
Listen to webcast
May 7, 2020
at 4:30 PM EDT
Dynavax Technologies First Quarter 2020 Financial Results
Listen to webcast
Apr 30, 2020
at 10:00 AM PDT
HEPLISAV-B Dialysis Study Interim Data
Replay Webinar
Mar 11, 2020
at 4:30 PM EDT
Dynavax Technologies Fourth Quarter and Full Year 2019 Financial Results
Listen to webcast
Mar 2, 2020
at 1:30 PM EST
Cowen and Company's 40th Annual Health Care Conference
Listen to webcast
Nov 6, 2019
at 4:30 PM EST
Dynavax Technologies Third Quarter 2019 Financial Results
Listen to webcast

Presentations

Date Documents
Jun 03, 2019
Abstract 9555: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
Jun 03, 2019
Abstract 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
Jun 01, 2019
Abstract 6039: Phase 1b/2, Open-Label, Multicenter Study of Intratumoral SD-101 in Combination With Pembrolizumab in Anti-PD-1 Treatment- Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT025218
Apr 02, 2019
Abstract 8304: Phase 1b, Open Label, Multicenter Study of Inhaled DV281, a Toll-like Receptor 9 Agonist, in Combination with Nivolumab in Patients with Second-or Third-Line Advanced or Metastatic Non Small Cell Lung Cancer (NCT03326752)
Apr 01, 2019
Abstract # 2259 Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, Domatinostat
Nov 12, 2018
Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types
Oct 21, 2018
Abstract 3781: Phase 1b/2, Open-Label, Multicenter Study of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Advanced Melanoma Resistant/Refractory to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
Oct 20, 2018
Phase 1b/2, Open-Label, Multicenter Study of Intratumoral SD-101 in Combination With Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Abstract 3560)
Oct 20, 2018
LBA45: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
Jun 26, 2018
HEPLISAV-B®, 2-Dose Hepatitis B Vaccine Using a Toll-like Receptor 9 Adjuvant, is Well Tolerated and Induces Higher Rates of Seroprotection than Engerix-B in Persons with Diabetes Aged 60 Years or Older